What Payers Need to See From New Complicated UTI Therapies

This episode, "What Payers Need to See From New Complicated UTI Therapies," has the panel turning to the financial and payer-facing side of complicated urinary tract infection management.

Dr. Gupta turns to Dr. Pogue to explore the financial and operational side of complicated UTI, including length of stay and staffing pressures. Dr. Pogue notes that length of stay is already a major target for hospital administrators. Stewardship programs have long looked for ways to shorten stays tied to community-acquired pneumonia, skin infections, and UTI alike. Transitioning patients to oral therapy and facilitating discharge remains one lever. He highlights an underappreciated staffing cost: a program called Jabs to Tabs, led by a United Kingdom-based pharmacist, tracked nurses to measure the true burden of administering intravenous antibiotics. That work found each intravenous dose added roughly twenty minutes of nursing time once preparation, retrieval, and administration were counted. A three-times-daily drug therefore consumes a full extra hour of nursing time per patient. Multiplied across a hospital's total antibiotic doses, Dr. Pogue argues oral options offer staffing benefits well beyond the traditional cost conversation. Dr. Gupta then asks Dr. Kaye what payers need to see before embracing newer complicated UTI therapies. Dr. Kaye identifies unmet need as the first requirement, warning that a "me-too" antibiotic offering nothing beyond existing generics will not fare well with pharmacy and therapeutics committees. Safety is the second pillar, particularly given how common UTI is and how easily drug-drug interactions can complicate care. The third is demonstrated effectiveness: evidence that a new antibiotic produces faster improvement, shorter hospitalization, and quicker return to baseline function than existing therapies. Dr. Kaye suggests unmet need can be argued even before launch. The more robust safety and economic outcome data, though, typically only emerges in postmarketing, phase four-style research once an agent reaches real-world use.

Our next episode, "Building the Case for New Complicated UTI Treatments," turns to what it actually takes to get a promising new agent from formulary approval into everyday use.